Combined use of transurethral vaporization and resection for benign prostatic hyperplasia: Clinical study of 122 cases / 中国微创外科杂志

Objective To summarize the effect of transurethral vaporization of the prostate (TUVP) in combination with transurethral resection of the prostate (TURP) for the treatment of benign prostatic hyperplasia (BPH). Methods A combined use of TUVP and TURP was carried out for treating 122 cases of BPH. There were 8 cases of Rous stage Ⅰ disease, 58 cases of stage Ⅱ, 32 cases of stage Ⅲ, and 24 cases of Ⅳ. Results The length of duration of the operation was 20~140 min (mean, 68 min). The intraoperative blood loss was 40~200 ml (mean, 80 ml). A blood transfusion of 200 ml was required in 2 cases after the operation. No transurethral resection syndrome (TURS) occurred. The mean postoperative catheterization time was 6 days. All 122 patients had been followed for 4~19 months (mean, 10 months). The international prostate symptom score (IPSS) decreased from 30.2?2.3 pre-)operation to 10.8?2.5 post-operation (t=10.84,P=0.000); the residual urine (RU) decreased from 252.6?65.3 ml pre-operation to 35.6?10.4 ml post-operation (t=23.52,P=0.000); the maximum urinary flow rate (Qmax) increased from 8.5?2.8 ml/s to 20.6?3.8 ml/s (t=6.67,P=0.000). Postoperatively, transient urinary incontinence was observed in 2 cases, and anterior urethral stricture occurred in 2 cases. Conclusions Combined use of transurethral electrovaporization and resection of the prostate for the treatment of BPH gives satisfactory effects.

Comparison of the therapeutic effect of several drugs infused into the bladder for superficial tumors after transurethral resection of the bladder tumor / 中国癌症杂志

Purpose:To compare the therapeutic effect and significance of different drugs poured in intravesical instillation for superficial biadder tumor after transurethral resection of bladder tumor.Methods:117 patients of superficial bladder cancer after transurethral vesection were divided into four groups. Ballistocardiogram group(n=26);Mitomycin C group (n=27);adriamycin group (n=27);hydroxycamptothecin group(n=37).Results:The tumor recurrent rate in Ballistocardiogram group, mitomycin groups, adriamycin group, hydroxycamptothecin group were 30.77%,40.74% 33.33%,24.32% respectively. The tumor recurrent rate differed significantly between the hydroxycamptothecin group and the mitomycin and Adriamycin groups.Conclusions:Intravesical instillation of hydroxycamptothecin for patients with superficial bladder tumor after transurethral resection of bladder tumour could decrease tumor recurrent rate, prolong the tumor-free survival period.